Invasive Risk Stratification: When is it needed?

Size: px
Start display at page:

Download "Invasive Risk Stratification: When is it needed?"

Transcription

1 Inherited Cardiomyopathies and Channelopathies: Who is at risk for Sudden Cardiac Death? Invasive Risk Stratification: When is it needed? Hung-Fat Tse, MD, PhD Department of Medicine The University of Hong Kong Queen Mary Hospital Hong Kong

2 Inherited channelopathies Long QT Syndrome Short QT Syndrome Catecholaminergic polymorphic ventricular tachycardia Brugada Syndrome

3 Inherited channelopathies Long QT Syndrome Short QT Syndrome Catecholaminergic polymorphic ventricular tachycardia Brugada Syndrome

4 Long QT Syndrome 15 pts with LQTS with syncope or cardiac arrest Neither the inducibility of non-sustained VT nor the results of drug testing with beta- blockers proved to be of any prognostic value Spontaneous and Inducible VF in patients with LQTS Conclusion: EPS are of limited value in the diagnosis and treatment of pts with LQTS Bhandari AK, et al. Circulation 1985;71: 63-71

5 Short QT Syndrome 18 pts with SQTS presented with syncope/scd or Dx during family screening underwent EPS mean vent ERP 155ms (CL ms) and 150ms (CL ), and inducible VF in 11/18 (61%). In 6 pts with VF and SCD, only 3 pts (50%) had inducible VF on EPS. Conclusion: EPS are of limited value in the diagnosis and treatment of pts with SQTS Giustetto C, et al. Eur Heart J 2006;27:

6 Inherited channelopathies Long QT Syndrome Short QT Syndrome Catecholaminergic polymorphic ventricular tachycardia Brugada Syndrome

7 Catecholaminergic polymorphic ventricular tachycardia 19 pts with CPVT underwent EPS Polymorphic non-sustained VT was induced by EPS in 2/19 (11%) pts and 6 pts (31%) with polymorphic non-sustained VTwas induced during isoproterenol infusion 11/19 pts (58%) were not inducible. Conclusions: Low sensitivity and specificity of EPS for symptomatic CPVT pts Priori SG, et al. Circulation 2002;106;

8 Inherited channelopathies Long QT Syndrome Short QT Syndrome Catecholaminergic polymorphic ventricular tachycardia Brugada Syndrome

9 Brugada Syndrome Benito B, et al. Prog Cardiovas Dis 2008;51:1-22

10 Variation of ECG Pattern in Brugada Syndrome Richter S, et al. Eur Heart J 2010

11 PHARMACOLOGICAL TESTS Suspicion of Brugada Syndrome and a nondiagnostic ECG Drug challenge tests Drug Dosage and Administration (3) Ajmaline 1 mg/kg over 5 min, IV Flecainide 2 mg/kg over 10 min, IV (400 mg, PO) Procainamide 10 mg/kg over 10 min, IV Plisicainide 1 mg/kg over 10 min, IV Never forget to place V 1 and V 2 in 2 nd And 3 rd intercostal space!!! 1. Hong et al. Circ Meregalli et al JCE Antzelevich et al. Circ Mivamoto et al. Am J Cardiol. 2007

12 Brugada Syndrome Benito B, et al. Prog Cardiovas Dis 2008;51:1-22

13 Benito B, et al. Prog Cardiovas Dis 2008;51:1-22

14 Brugada Series Patients Without Prior Cardiac Arrest Multivariate analysis (Independent predictors of events) HR 95% CI P Inducibility in EPS Syncope Basal ECG Inducible Non inducible ECG+syncope ECG+asymptomatic ECG-syncope ECG - asymptomatic Berruezo AJ. HRS 2010

15 Brugada Series Probability of SCD During Life-Time 45, ,5 23,4 4, Inducible Non inducible 11 7,6 ECG - male ECG - female ECG + male ECG + female Berruezo AJ. HRS 2010

16 Brugada Series: ICD Pts SYMPTOMS Yes : sudden death 79 patients Events : 37/79 (47%) HIGH RISK Yes : syncope 81 patients Events : 21/81 (26%) HIGH RISK No (asymptomatic) 98 patients Events : 11/98 (11%) INTERMEDICATE RISK BASAL ECG Abnormal 83 patients Events : 11/83 (13%) INTERMEDICATE RISK Normal 15 patients Events : 0/15 (0%) LOW RISK Yes 68 patients Events : 11/68 (16%) INTERMEDICATE RISK INDUCIBILITY ON EPS No 15 patients Events : 0/15 (0%) LOW RISK Berruezo AJ. HRS 2010

17 Number of Patients with EPS Electrophysiological Study in Brugada Syndrome % % 250 Brugada series % 23% Others % 23% Cardiac Arrest Syncope Asymptomatic Paul M, et al. Eur Heart J 2007; 28:

18 Asymptomatic Brugada Syndrome Paul M, et al. Eur Heart J 2007; 28:

19 % of Patients Asymptomatic Brugada Syndrome 2% VF % VF % VF 4% VF Others 10 0 EPS -ve EPS +ve Brugada series Paul M, et al. Eur Heart J 2007; 28:

20 Asymptomatic Brugada Syndrome Japanese Probands N=330, mean age pts underwent EPS 57% of asymptomatic pt (n=154, 63%) with inducible VF Mean FU 4 yrs European Probands N=1029, mean age pts underwent EPS 37% of asymptomatic pt (n=654, 64%) with inducible VF Mean FU 3 yrs Kamakura S, et al. Circ Arrhythm EP 2009 Probst et al. Circulation 2009

21 Asymptomatic Brugada Syndrome 100 Japanese Study Europe (FINGER) Study Arrhythmia free survival Asymptomatic Arrhythmia free survival Asymptomatic 100 Syncope Syncope 80% Cardiac arrest 80% Cardiac arrest 60% 60% Months follow-up Drug-induced Type I Months follow-up 100 Drug-induced Type I 80% Spontaneous Type I 80% Spontaneous Type I p= Months follow-up 70 Kamakura S, et al. Circ Arrhythm EP 2009 p= Months follow-up Probst et al. Circulation 2009

22 Asymptomatic Brugada Syndrome Data on outcome of asymptomatic patients with type I Brugada ECG with INDCIBLE VF Japanese Study Spontaneous Type I 57 Inducible VF Drug-induced type I (56%) 20 (58%) Spontaneous VF at 4 years 1/32 = 3% 0/20 = 0 1/52 = 2% Europe FINGER Study Spontaneous Type I 172 Inducible VF Drug-induced type I (37%) 74 (37%) Spontaneous VF at 5 years 1/63 = 2% 3/74 = 4% 4/137 = 3% Kamakura S, et al. Circ Arrhythm EP 2009 Probst et al. Circulation 2009

23 Asymptomatic Brugada Syndrome Japanese Study Arrhythmia free survival Europe (FINGER) Study Arrhythmia free survival 100 Negative EPS 100 Negative EPS 80% Inducible VF 80% Inducible VF p=0.16 p= % 60% 40% Follow-up (months) 40% Follow-up (months)

24 Data on outcome of asymptomatic patients with type I Brugada ECG with INDUCIBLE VF Data on the Japanese Study and the European FINGER study combined This risk for arrhythmic events -- at 4-5 years -- for asymptomatic patients with inducible VT is : 1/52 + 4/137 = 5/189 = 2.6% Upper limit of the 95% confidence interval = 6% Japanese Study Europe FINGER Study Brugada Series 6% 1/52 + 4/ /68 = 16/257 Viskin S. HRS 2010

25 Data on outcome of asymptomatic patients with type I Brugada ECG with NEGATIVE EPS Data on the Japanese Study and the European FINGER study combined This risk for arrhythmic events -- at 4-5 years -- for asymptomatic patients who are NOT inducible 2/39 + 2/76 = 4/115 = 3.5% Upper limit of the 95% confidence interval = 8% And for asymptomatic patients with spontaneous Type I who are NOT inducible : 2/25 + 2/109 = 4/134 = 3% Upper limit of the 95% confidence interval = 7% Viskin S. HRS 2010

26 Current ACC/AHA/ESC Guideline Long QTS/ CPVT No recommendation for EP testing Brugada Syndrome Class IIb. EP testing may be considered for risk assessment for SCD in pts with ARVC/D (level of evidence C)

27 Inherited Cardiomyopathy Hypertrophic Cardiomyopathy Arrhythmogenic Right Ventricular Cardiomyopathy Maron BJ. Cardiovas Path 2010 Buja G, et al. Prog Cardiovas Dis 2008

28 Hypertrophic Cardiomyopathy Asymptomatic Symptomatic Pts with inducible VT on EPS had higher event rate But, predictive accuracy is very low Fananapazir L, et al. Circulation 1992

29 Arrhythmogenic Right Ventricular Cardiomyopathy The prognostic role of EPS in patients with ARVC/D is controversial. Majority of data are based on retrospective analysis of ARVD pts who underwent ICD implant low predictive accuracy of EPS in pts with definite ARVC/D Pts with probable ARVC/D and ve EP study may represent a low risk group Roguin A, et al. JACC 2004 Piccini JP, et al. Heart Rhythm 2005

30 Current ACC/AHA/ESC Guideline Hypertrophic Cardiomyopathy Class IIb. EP testing may be considered for risk assessment for SCD in pts with HCM (level of evidence C) Arrhythmogenic Right Ventricular Cardiomyopathy Class IIb. EP testing may be considered for risk assessment for SCD in pts with ARVC/D (level of evidence C)

31 Conclusions Risk stratification for SCD with EP study in subjects with inherited channelopathy and cardiomyopathy remain challenging No role for invasive EP study in symptomatic pts with LQTS/SQTS/CPVT, but role in asymptomatic subjects unclear? Controversy over the role of EP study in asymptomatic Brugada syndrome/hocm and ARVD role in uncertain case?

Name of Presenter: Marwan Refaat, MD

Name of Presenter: Marwan Refaat, MD NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010 I have no actual or potential conflict of interest in relation

More information

Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?

Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? Innovations in Interventional Cardiology and Electrophysiology Thessaloniki 2014 Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? K. Letsas, MD, FESC

More information

Ripolarizzazione precoce. Torino, 24th October Non così innocente come si pensava

Ripolarizzazione precoce. Torino, 24th October Non così innocente come si pensava Asymptomatic inherited arrhythmia syndromes: Drug induced Brugada Syndrome: when a prophylactic ICD is indicated? how high (or low) is QT the risk? Asymptomatic short Ripolarizzazione precoce. Torino,

More information

Pearls of the ESC/ERS Guidelines 2015 Channelopathies

Pearls of the ESC/ERS Guidelines 2015 Channelopathies Pearls of the ESC/ERS Guidelines 2015 Channelopathies Carina Blomstrom Lundqvist Dept Cardiology, Uppsala, Sweden Content 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias

More information

Ripolarizzazione precoce. Non così innocente come si pensava

Ripolarizzazione precoce. Non così innocente come si pensava La sincope nel paziente con ECG Brugada-like Stresa, 9 giugno 2017 Ripolarizzazione precoce. Non così innocente come si pensava Carla Giustetto Carla Giustetto Divisione di Cardiologia Divisione Università

More information

The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes

The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes RHEA C. PIMENTEL, MD, FACC, FHRS UNIVERSITY OF KANSAS HOSPITAL MID AMERICA CARDIOLOGY AUGUST 19, 2012 Monogenic Arrhythmia Syndromes Mendelian

More information

Ripolarizzazione precoce. Non così innocente come si pensava

Ripolarizzazione precoce. Non così innocente come si pensava Brugada syndrome: tests and diagnosis. Torino, 27 ottobre 2017 Ripolarizzazione precoce. Non così innocente come si pensava Carla Giustetto Carla Giustetto Divisione di Cardiologia Divisione Università

More information

ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ

ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ ΤΙ ΠΡΕΠΕΙ ΝΑ ΓΝΩΡΙΖΕΙ ΟΓΕΝΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΓΙΑ ΤΙΣ ΔΙΑΥΛΟΠΑΘΕΙΕΣ ΣΤΕΛΙΟΣ ΠΑΡΑΣΚΕΥΑÏΔΗΣ ΔΙΕΥΘΥΝΤΗΣ ΕΣΥ Α Καρδιολογική Κλινική ΑΠΘ, Νοσοκομείο ΑΧΕΠΑ, Θεσσαλονίκη NO CONFLICT OF INTEREST Sudden Cardiac Death

More information

Tailored treatment in Brugada syndrome

Tailored treatment in Brugada syndrome Tailored treatment in Brugada syndrome Lars Eckardt Department of Cardiology and Angiology Division of Experimental and Clinical Electrophysiology University of Münster, Germany 45 yr old male preoperative

More information

The impact of clinical and genetic findings on the management of young Brugada Syndrome patients

The impact of clinical and genetic findings on the management of young Brugada Syndrome patients 12 ème Congrès Médico-Chirugical de la FCPC 21 au 24 novembre 2015 Schoelcher, Martinique The impact of clinical and genetic findings on the management of young Brugada Syndrome patients Institut du Thorax,

More information

Tachycardia Devices Indications and Basic Trouble Shooting

Tachycardia Devices Indications and Basic Trouble Shooting Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and

More information

State of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification

State of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification State of the Art: Brugada Syndrome Novel diagnostic approaches and risk stratification Lars Eckardt Division Electrophysiology Department of Cardiovascular Medicine University of Münster, Germany I have

More information

FANS Paediatric Pathway for Inherited Arrhythmias*

FANS Paediatric Pathway for Inherited Arrhythmias* FANS Paediatric Pathway for Inherited Arrhythmias* The pathway is based on the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes

More information

Asymptomatic Long QT. Prof. Dr. Martin Borggrefe Mannheim

Asymptomatic Long QT. Prof. Dr. Martin Borggrefe Mannheim Asymptomatic Long QT Prof. Dr. Martin Borggrefe Mannheim QT interval Distribution of QTc intervals in large population-based studies Viskin S, Heart Rhythm 2009; 6: 711-715 QT interval Distribution of

More information

When VF is the endpoint, wait and see is not always the best option.

When VF is the endpoint, wait and see is not always the best option. Being free of symptoms does not necessarily mean free of arrhythmias. This Holter is from a asymptomatic 48 years old female with LQT2 When VF is the endpoint, wait and see is not always the best option.

More information

Ripolarizzazione precoce.

Ripolarizzazione precoce. Controversia: impianto di defibrillatore in prevenzione primaria Caso clinico: Ripolarizzazione precoce. Sindrome di Brugada Non così innocente come si pensava Torino, 31 marzo 2017 Carla Giustetto Carla

More information

WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY

WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY Learning Objectives to Disclose: To CRITIQUE the ICD and its role in the treatment of BrS, CPVT, and LQTS WINDLAND SMITH RICE SUDDEN DEATH GENOMICS LABORATORY Conflicts of Interest to Disclose: Consultant

More information

Silvia G Priori MD PhD

Silvia G Priori MD PhD The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics

More information

Pattarapong Makarawate MD, FHRS Assistant Professor. Division Of Cardiology Faculty of Medicine, Khon Kaen University

Pattarapong Makarawate MD, FHRS Assistant Professor. Division Of Cardiology Faculty of Medicine, Khon Kaen University Pattarapong Makarawate MD, FHRS Assistant Professor. Division Of Cardiology Faculty of Medicine, Khon Kaen University 1. Important and impact of ICD in primary prevention 2. Risk stratification for ICD

More information

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden

More information

Prevention of Sudden Death in ARVC

Prevention of Sudden Death in ARVC ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück

More information

How agressively should we treat asymptomatic patients with Brugada syndrome. Josep Brugada Medical Director Hospital Clínic, University of Barcelona

How agressively should we treat asymptomatic patients with Brugada syndrome. Josep Brugada Medical Director Hospital Clínic, University of Barcelona How agressively should we treat asymptomatic patients with Brugada syndrome Josep Brugada Medical Director Hospital Clínic, University of Barcelona The ECG in Brugada syndrome - Prolonged PR - RBBB - ST

More information

Are there low risk patients in Brugada syndrome?

Are there low risk patients in Brugada syndrome? Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the

More information

ARVC when TO IMPLANT THE ASYMPTOMATIC PERSON

ARVC when TO IMPLANT THE ASYMPTOMATIC PERSON EUROPACE 2011 INHERITED ELECTRICAL CARDIAC DISORDERS ARVC when TO IMPLANT THE ASYMPTOMATIC PERSON June 26 th 2011 Robert Lemery MD CONFLICTS of INTEREST None ASYMPTOMATIC ARVC 1. ECG 2. ASYMPTOMATIC PVC

More information

SEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !

SEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers ! Sudden cardiac death in the adult Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel.! " # $ % Cancers National Vital Statistics Report, Vol 49 (11), Oct. 12, 2001. 20% 25% State-specific

More information

What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment. Andreas Pflaumer

What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment. Andreas Pflaumer What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment Andreas Pflaumer Diagnosis of CPVT Induction of different types of VES or VT by exercise or catecholamines AND exclusion of of other

More information

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Adenosine in idiopathic AV block, 445 446 Adolescent(s) syncope in, 397 409. See also Syncope, in children and adolescents AECG monitoring.

More information

What Every Physician Should Know:

What Every Physician Should Know: What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer

More information

Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.

Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart. Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart. Hanne Rasmusen Consultant cardiologist, PhD Dept. of Cardiology Bispebjerg University Hospital

More information

Asymptomatic WPW Syndrome; Observation or Ablation? 전남대학교병원순환기내과 박형욱

Asymptomatic WPW Syndrome; Observation or Ablation? 전남대학교병원순환기내과 박형욱 Asymptomatic WPW Syndrome; Observation or Ablation? 전남대학교병원순환기내과 박형욱 Let It Be? Vs. Just Do It? Natural history of asymptomatic WPW Incidence of sudden cardiac death in natural history studies involving

More information

WPW in Athletes Should we treat all? age? RAMI FOGELMAN SCHNEIDER CHILDREN MEDICAL CENTER OF ISRAEL

WPW in Athletes Should we treat all? age? RAMI FOGELMAN SCHNEIDER CHILDREN MEDICAL CENTER OF ISRAEL WPW in Athletes Should we treat all? age? RAMI FOGELMAN SCHNEIDER CHILDREN MEDICAL CENTER OF ISRAEL W.P.W Clues in sinus rhythm No Q in Lt chest leads (WPW 88%, control 5%) PR < 100msec (WPW 80%, control

More information

Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification

Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Drugs Controlling Myocyte Excitability and Conduction at the AV node Singh and Vaughan-Williams Classification Class I Na Channel Blockers Flecainide Propafenone Class III K channel Blockers Dofetilide,

More information

How to manage a patient with short QT syndrome?

How to manage a patient with short QT syndrome? How to manage a patient with short QT syndrome? Torino, 27 ottobre2012 Carla Giustetto Division of Cardiology University of Torino QT 280 ms QTc 260 ms Narrow, tall and peaked T waves High incidence of

More information

Adult Complexities of the Channelopathies

Adult Complexities of the Channelopathies Adult Complexities of the Channelopathies Andrew Krahn MD FHRS Sauder Family and Heart and Stroke Foundation Chair in Cardiology Paul Brunes Chair in Heart Rhythm Disorders University of British Columbia

More information

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Genetic Testing for Page 1 of 23 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Genetic Testing for Professional Institutional Original Effective Date: August

More information

SUDDEN CARDIAC DEATH(SCD): Definition

SUDDEN CARDIAC DEATH(SCD): Definition SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY

More information

Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F

Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very

More information

Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες

Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou

More information

SUDDEN CARDIAC DEATH(SCD): Definition

SUDDEN CARDIAC DEATH(SCD): Definition SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY

More information

Παναγιώτης Ιωαννίδης. Διευθυντής Τμήματος Αρρυθμιών & Επεμβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών

Παναγιώτης Ιωαννίδης. Διευθυντής Τμήματος Αρρυθμιών & Επεμβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών Διαστρωμάτωση κινδύνου για αιφνίδιο καρδιακό θάνατο σε ασθενείς που δεν συμπεριλαμβάνονται σε μεγάλες κλινικές μελέτες «Ασθενείς με ηλεκτρικά νοσήματα» Παναγιώτης Ιωαννίδης Διευθυντής Τμήματος Αρρυθμιών

More information

Genetic Testing for Cardiac Ion Channelopathies

Genetic Testing for Cardiac Ion Channelopathies Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada

Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada Διαχείρηση Ασυμπτωματικού ασθενούς με ΗΚΓ τύπου Brugada Άννα Κωστοπούλου Επιμελήτρια Α Ωνάσειο Καρδιοχειρουργικό Κέντρο Τμήμα Ηλεκτροφυσιολογίας και Βηματοδότησης BrS: Diagnosis 5:10000 First described

More information

Sudden Cardiac Death in Sports: Causes and Current Screening Recommendations

Sudden Cardiac Death in Sports: Causes and Current Screening Recommendations Sports Cardiology Sudden Cardiac Death in Sports: Causes and Current Screening Recommendations Domenico Corrado, MD, PhD Inherited Arrhytmogenic Cardiomyopathy Unit Department of Cardiac, Thoracic and

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Testing for Cardiac Ion Channelopathies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_cardiac_ion_channelopathies 10/2008 4/2018

More information

Section: Effective Date: Subsection: Original Policy Date: Subject: Page: Last Review Status/Date: Background

Section: Effective Date: Subsection: Original Policy Date: Subject: Page: Last Review Status/Date: Background Genetic Testing for Cardiac Ion Last Review Status/Date: March 2014 Genetic Testing for Cardiac Ion Description Page: 1 of 22 Genetic testing is available for patients suspected of having cardiac ion channelopathies

More information

CHANNELOPATHIES IS GENETIC TESTING ESSENTIAL IN PTS MANAGEMENT

CHANNELOPATHIES IS GENETIC TESTING ESSENTIAL IN PTS MANAGEMENT CHANNELOPATHIES IS GENETIC TESTING ESSENTIAL IN PTS MANAGEMENT Inherited and Rare Cardiac Diseases Unit Heart Center for the Young and Athletes ONASSIS CARDIAC SURGERY CENTRE DIAGNOSIS ION CHANNEL DISEASE

More information

Risk Factors for Sudden cardiac Death

Risk Factors for Sudden cardiac Death Risk Factors for Sudden cardiac Death A. Arenal Arrhythmias in competitive sports Disclosure Conflict of interest Advisory board: Medtronic, Boston Scientific Research grants: Medtronic, Boston Scientific,

More information

Professor Eric Schulze-Bahr

Professor Eric Schulze-Bahr No CoI. Professor Eric Schulze-Bahr Institute for Genetics of Heart Diseases Department of Cardiology and Angiology University Hospital Münster / Germany ICD therapy in asymptomatic or borderline LQTS

More information

Patient Resources: Cardiac Channelopathies

Patient Resources: Cardiac Channelopathies Patient Resources: Cardiac Channelopathies Overview of Cardiac Channelopathies: CPVT, Long QT Syndrome and Brugada Syndrome Heart muscle cells contract because of movement of certain molecules (called

More information

Plotse hartdood & genetica

Plotse hartdood & genetica Onder spanning inspannen Utrecht, 17 April 2018 Plotse hartdood & genetica N. Hofman, PhD Academic Medical Centre Amsterdam, the Netherlands European Reference Network Network of centres in Europe sharing

More information

SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM

SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM Rio De Janeiro 2016 Sport and Exercise Cardiology Symposium SBC/SOCERJ ACC Sharlene M. Day, MD Associate Professor, Cardiovascular Medicine Director,

More information

Arrhythmias (II) Ventricular Arrhythmias. Disclosures

Arrhythmias (II) Ventricular Arrhythmias. Disclosures Arrhythmias (II) Ventricular Arrhythmias Amy Leigh Miller, MD, PhD Cardiovascular Electrophysiology, Brigham & Women s Hospital Disclosures None Rhythms and Mortality Implantable loop recorder post-mi

More information

WPW and Brugada syndrome: what do they have in common?

WPW and Brugada syndrome: what do they have in common? Ripolarizzazione precoce. Non così innocente come si pensava WPW and Brugada syndrome: what do they have in common? Carla Giustetto Prof. Divisione Fiorenzo di Cardiologia Gaita Ospedale S.Giovanni Battista

More information

Genetic Testing for Cardiac Ion Channelopathies

Genetic Testing for Cardiac Ion Channelopathies Genetic Testing for Cardiac Ion Channelopathies Policy Number: 2.04.43 Last Review: 11/2018 Origination: 6/2007 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide

More information

Brugada Syndrome: An Update

Brugada Syndrome: An Update Brugada Syndrome: An Update Osama Diab Associate professor of Cardiology Ain Shams university, Cairo, Egypt Updates Mechanism and Genetics Risk stratification Treatment 1 Brugada syndrome causes 4 12%

More information

Asaad Khoury 2,3 MD, Monther Boulos 1,3 MD, Mahmoud Suleiman 1,3 MD, Miry Blich 1,3 MD, Michael Eldar 4 MD, Ibrahim Marai 1,3 MD,

Asaad Khoury 2,3 MD, Monther Boulos 1,3 MD, Mahmoud Suleiman 1,3 MD, Miry Blich 1,3 MD, Michael Eldar 4 MD, Ibrahim Marai 1,3 MD, Flecainide therapy suppresses exercise induced ventricular arrhythmias in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia Asaad Khoury 2,3 MD, Monther Boulos 1,3 MD,

More information

Index. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A AEDs. See Automated external defibrillators (AEDs) AF. See Atrial fibrillation (AF) Age as factor in SD in marathon runners, 45 Antiarrhythmic

More information

The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia

The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology

More information

CME Article Brugada pattern masking anterior myocardial infarction

CME Article Brugada pattern masking anterior myocardial infarction Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review

More information

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012 IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the

More information

Ventricular arrhythmias

Ventricular arrhythmias Ventricular arrhythmias Assoc.Prof. Lucie Riedlbauchová, MD, PhD Department of Cardiology University HospitalMotol and2nd FacultyofMedicine, Charles University in Prague Definition and classification Ventricular

More information

Exercise-induced ventricular arrhythmias in CPVT patients occur at lower heart rate on beta-blocker therapy

Exercise-induced ventricular arrhythmias in CPVT patients occur at lower heart rate on beta-blocker therapy Exercise-induced ventricular arrhythmias in CPVT patients occur at lower heart rate on beta-blocker therapy Leren IS, Haugaa KH, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, Früh A, Edvardsen T, Kongsgård

More information

Preventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete

Preventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete Preventing Sudden Death in Young Athletes Ronn E. Tanel, MD Director, Pediatric Arrhythmia Service UCSF Children s Hospital Associate Professor of Pediatrics UCSF School of Medicine Outline Sudden death

More information

La valutazione dell atleta: è una strategia salva-vita e costo-efficace?

La valutazione dell atleta: è una strategia salva-vita e costo-efficace? La valutazione dell atleta: è una strategia salva-vita e costo-efficace? Primo trattato di Medicina Wilson and Jungner s criteria In the 1960s the World Health Organization adopted the Wilson and Jungner

More information

Primary Therapy for High Risk LQT Patients Should Be an ICD

Primary Therapy for High Risk LQT Patients Should Be an ICD Primary Therapy for High Risk LQT Patients Should Be an ICD Raul Weiss MD, FAHA, FACC, FHRS, CCDS Director, Electrophysiology Fellowship Program Associate Professor of Medicine The Ohio State University

More information

Wojciech Szczepański, MD, PhD Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division Medical University of Bialystok

Wojciech Szczepański, MD, PhD Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division Medical University of Bialystok Channelopathies: - Long QT syndrome - Short QT syndrome - Brugada syndrome - Early repolarization syndrome - Catecholaminergic polymorphic ventricular tachycardia Wojciech Szczepański, MD, PhD Department

More information

Case Presentation. Asaad Khan University College Hospital Galway Rep of Ireland

Case Presentation. Asaad Khan University College Hospital Galway Rep of Ireland Case Presentation Asaad Khan University College Hospital Galway Rep of Ireland Case History 32 male Married Working as a chartered accountant P/C:Admitted to a Regional hospital to be investigated for

More information

Treatment of VT of Purkinje fiber origin: ablation targets and outcome

Treatment of VT of Purkinje fiber origin: ablation targets and outcome Treatment of VT of Purkinje fiber origin: ablation targets and outcome Ch. Piorkowski University Leipzig - Heart Center - Dept. of Electrophysiology Leipzig, Germany Presenter Disclosure Information Gerhard

More information

Secondary prevention of sudden cardiac death

Secondary prevention of sudden cardiac death Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary

More information

Supraventricular arrhythmias in Brugada syndrome. Prof. Dr. Martin Borggrefe Mannheim

Supraventricular arrhythmias in Brugada syndrome. Prof. Dr. Martin Borggrefe Mannheim Supraventricular arrhythmias in Brugada syndrome Prof. Dr. Martin Borggrefe Mannheim Brugada syndrome 1992-2012 Time interval between description of the disease and discovery of first causal gene Brugada

More information

Outflow Tract Ventricular Tachycardia Always Benign?

Outflow Tract Ventricular Tachycardia Always Benign? Outflow Tract Ventricular Tachycardia Always Benign? Arash Arya, M.D. Department of Interventional Electrophysiology Heart Center University of Leipzig Disclosures: NONE Outflow Ventricular Tachycardia

More information

Ενδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν»

Ενδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν» Ενδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν» Major Implantable Cardioverter-Defibrillator Trials for Prevention

More information

Tachycardias II. Štěpán Havránek

Tachycardias II. Štěpán Havránek Tachycardias II Štěpán Havránek Summary 1) Supraventricular (supraventricular rhythms) Atrial fibrillation and flutter Atrial ectopic tachycardia / extrabeats AV nodal reentrant a AV reentrant tachycardia

More information

Investigating the family after a sudden cardiac death. Dr Catherine Mercer Consultant Clinical Geneticist, Wessex

Investigating the family after a sudden cardiac death. Dr Catherine Mercer Consultant Clinical Geneticist, Wessex Investigating the family after a sudden cardiac death Dr Catherine Mercer Consultant Clinical Geneticist, Wessex Sudden adult deaths subdivided Sudden Adult Death Sudden Cardiac Death Sudden Arrhythmic

More information

ICD in a young patient with syncope

ICD in a young patient with syncope ICD in a young patient with syncope Konstantinos P. Letsas, MD, FESC Second Department of Cardiology Evangelismos General Hospital of Athens Athens, Greece Case presentation A 17-year-old apparently healthy

More information

Subcutaneous Implantable Cardioverter Defibrillator (ICD) System

Subcutaneous Implantable Cardioverter Defibrillator (ICD) System Subcutaneous Implantable Cardioverter Defibrillator (ICD) System Policy Number: Original Effective Date: MM.06.025 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 3/24/201701/01/2019

More information

Management of Syncope in Heart Failure. University of Iowa

Management of Syncope in Heart Failure. University of Iowa Management of Syncope in Heart Failure Brian Olshansky University of Iowa 1 Syncope Transient loss of consciousness, with rapid, usually complete, recovery, with or without prodrome A common, non-specific,

More information

The patient with (without) an ICD and heart failure: Management of electrical storm

The patient with (without) an ICD and heart failure: Management of electrical storm ISHNE Heart Failure Virtual Symposium April 2008 The patient with (without) an ICD and heart failure: Management of electrical storm Westfälische Wilhelms-Universität Münster Günter Breithardt, MD, FESC,

More information

Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD

Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD Basics of Structure/Function of Sodium and Potassium Channels Barry London, MD PhD University of Pittsburgh Medical Center Pittsburgh, PA International Symposium of Inherited Arrhythmia Disorders and Hypertrophic

More information

Description. Page: 1 of 31. Genetic Testing for Cardiac Ion Channelopathies. Last Review Status/Date: December 2015

Description. Page: 1 of 31. Genetic Testing for Cardiac Ion Channelopathies. Last Review Status/Date: December 2015 Genetic Testing for Cardiac Ion Last Review Status/Date: December 2015 Genetic Testing for Cardiac Ion Description Page: 1 of 31 Genetic testing is available for patients suspected of having cardiac ion

More information

Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France

Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France Syncope in advanced heart failure: high risk of sudden death N = 491 patients with HF (NYHA III-IV)

More information

Active Cascade Screening in Primary Inherited Arrhythmia Syndromes

Active Cascade Screening in Primary Inherited Arrhythmia Syndromes Journal of the American College of Cardiology Vol. 55, No. 23, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.12.063

More information

Strength and weakness of genetic testing in clinical routine.

Strength and weakness of genetic testing in clinical routine. Strength and weakness of genetic testing in clinical routine. Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular

More information

Sudden Cardiac Death and Asians Disclosures

Sudden Cardiac Death and Asians Disclosures Sudden Cardiac Death and Asians Disclosures 7 February 2009 Asian Heart and Vascular Symposium None Zian H. Tseng, M.D., M.A.S. Assistant Professor of Medicine Cardiac Electrophysiology Section University

More information

DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY. David SIU MD ( 蕭頌華醫生 ) Division of Cardiology The University of Hong Kong

DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY. David SIU MD ( 蕭頌華醫生 ) Division of Cardiology The University of Hong Kong APHRS Summit 2018 in conjunction with HKCC Heart Rhythm Refresher Course DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY David SIU MD ( 蕭頌華醫生 ) Division of Cardiology The University of Hong Kong

More information

Sudden cardiac death: Primary and secondary prevention

Sudden cardiac death: Primary and secondary prevention Sudden cardiac death: Primary and secondary prevention By Kai Chi Chan Penultimate Year Medical Student St George s University of London at UNic Sheba Medical Centre Definition Sudden cardiac arrest (SCA)

More information

P. Brugada 1, R. Brugada 2 and J. Brugada 3. Introduction. U.S.A.; 3 Unitat d Arritmias, Hospital Clinic, Barcelona, Spain

P. Brugada 1, R. Brugada 2 and J. Brugada 3. Introduction. U.S.A.; 3 Unitat d Arritmias, Hospital Clinic, Barcelona, Spain European Heart Journal (2000) 21, 321 326 Article No. euhj.1999.1751, available online at http://www.idealibrary.com on Sudden death in patients and relatives with the syndrome of right bundle branch block,

More information

Spontaneous type 1 pattern, ventricular arrhythmias and sudden cardiac death in Brugada Syndrome: an updated systematic review and meta-analysis

Spontaneous type 1 pattern, ventricular arrhythmias and sudden cardiac death in Brugada Syndrome: an updated systematic review and meta-analysis Journal of Geriatric Cardiology (2017) 14: 639 643 2017 JGC All rights reserved; www.jgc301.com Letter to the Editor Open Access Spontaneous type 1 pattern, ventricular arrhythmias and sudden cardiac death

More information

Genetic Testing for Cardiac Ion Channelopathies. Description

Genetic Testing for Cardiac Ion Channelopathies. Description Genetic Testing for Cardiac Ion Page: 1 of 30 Last Review Status/Date: March 2017 Genetic Testing for Cardiac Ion Description Genetic testing is available for patients suspected of having cardiac ion channelopathies

More information

HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital

HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital 1 2 Sudden death an unexpected natural death within a short time period, generally 1 hour or less from the onset

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Implantable Cardioverter Defibrillators Page 1 of 44 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Implantable Cardioverter Defibrillators Wearable Cardioverter

More information

La strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole

La strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole La strategia diagnostica: il monitoraggio ecg prolungato Michele Brignole ECG monitoring and syncope In-hospital monitoring Holter Monitoring External loop recorder Remote (at home) telemetry Implantable

More information

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology

More information

Abbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1

Abbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1 2017 AHA/ACC/HRS Systematic Review for the Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Data Supplement Table of Contents Part 1. For Asymptomatic

More information

HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW?

HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW? HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW? Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens LANCET 2013 ESC HCM

More information

What You Should Know About Subcutaneous and Transvenous ICD

What You Should Know About Subcutaneous and Transvenous ICD What You Should Know About Subcutaneous and Transvenous ICD N. A. Mark Estes III MD Professor of Medicine Tufts University School of Medicine Director, New England Cardiac Arrhythmia Center Tufts Medical

More information

2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC

2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC 2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential

More information

Who does not need a primary preventive ICD?

Who does not need a primary preventive ICD? Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense

More information

Sudden Cardiac Death in the Young: Advances in Risk-stratification and Treatment

Sudden Cardiac Death in the Young: Advances in Risk-stratification and Treatment PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 25 NO. 1 (8 15) Sudden Cardiac Death in the Young: Advances in Risk-stratification and Treatment Michael J. Silka and Yaniv Bar-Cohen Division of Cardiology,

More information